CYP2A13

Cytochrome P450, family 2, subfamily A, polypeptide 13

PDB rendering based on 1z10.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
SymbolsCYP2A13 ; CPAD; CYP2A; CYPIIA13
External IDsOMIM: 608055 MGI: 88596 HomoloGene: 85917 IUPHAR: 1323 GeneCards: CYP2A13 Gene
EC number1.14.14.1
RNA expression pattern
More reference expression data
Orthologs
SpeciesHumanMouse
Entrez155313086
EnsemblENSG00000197838ENSMUSG00000074254
UniProtQ16696P15392
RefSeq (mRNA)NM_000766NM_009997
RefSeq (protein)NP_000757NP_034127
Location (UCSC)Chr 19:
41.59 – 41.6 Mb		Chr 7:
26.31 – 26.32 Mb
PubMed search

Cytochrome P450 2A13 is a protein that in humans is encoded by the CYP2A13 gene.[1][2][3]

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum. Although its endogenous substrate has not been determined, it is known to metabolize 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a major nitrosamine specific to tobacco. This gene is part of a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q.[3]

References

  1. ↑ Fernandez-Salguero P, Hoffman SM, Cholerton S, Mohrenweiser H, Raunio H, Rautio A, Pelkonen O, Huang JD, Evans WE, Idle JR et al. (Oct 1995). "A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles". Am J Hum Genet 57 (3): 651–60. PMC 1801261. PMID 7668294.
  2. ↑ Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW (May 2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants". Pharmacogenetics 14 (1): 1–18. doi:10.1097/00008571-200401000-00001. PMID 15128046.
  3. ↑ 3.0 3.1 "Entrez Gene: CYP2A13 cytochrome P450, family 2, subfamily A, polypeptide 13".

Further reading

  • Fernandez-Salguero P, Gonzalez FJ (1995). "The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis.". Pharmacogenetics 5 (Special Issue): S123–8. doi:10.1097/00008571-199512001-00013. PMID 7581481.
  • Smith G, Stubbins MJ, Harries LW, Wolf CR (1999). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily.". Xenobiotica 28 (12): 1129–65. doi:10.1080/004982598238868. PMID 9890157.
  • Hoffman SM, Fernandez-Salguero P, Gonzalez FJ, Mohrenweiser HW (1996). "Organization and evolution of the cytochrome P450 CYP2A-2B-2F subfamily gene cluster on human chromosome 19.". J. Mol. Evol. 41 (6): 894–900. doi:10.1007/bf00173169. PMID 8587134.
  • Koskela S, Hakkola J, Hukkanen J et al. (1999). "Expression of CYP2A genes in human liver and extrahepatic tissues.". Biochem. Pharmacol. 57 (12): 1407–13. doi:10.1016/S0006-2952(99)00015-5. PMID 10353262.
  • Su T, Bao Z, Zhang QY et al. (2000). "Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.". Cancer Res. 60 (18): 5074–9. PMID 11016631.
  • Zhang X, Su T, Zhang QY et al. (2002). "Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant.". J. Pharmacol. Exp. Ther. 302 (2): 416–23. doi:10.1124/jpet.302.2.416. PMID 12130698.
  • Saito S, Iida A, Sekine A et al. (2003). "Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population.". J. Hum. Genet. 48 (5): 249–70. doi:10.1007/s10038-003-0021-7. PMID 12721789.
  • Wang H, Tan W, Hao B et al. (2004). "Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.". Cancer Res. 63 (22): 8057–61. PMID 14633739.
  • Cauffiez C, Lo-Guidice JM, Quaranta S et al. (2004). "Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility.". Biochem. Biophys. Res. Commun. 317 (2): 662–9. doi:10.1016/j.bbrc.2004.03.092. PMID 15063809.
  • Cheng XY, Chen GL, Zhang WX et al. (2004). "Arg257Cys polymorphism of CYP2A13 in a Chinese population.". Clin. Chim. Acta 343 (1–2): 213–6. doi:10.1016/j.cccn.2004.01.017. PMID 15115698.
  • He XY, Shen J, Ding X et al. (2005). "Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen". Drug Metab. Dispos. 32 (12): 1516–21. doi:10.1124/dmd.104.001370. PMID 15333516.
  • Fujieda M, Yamazaki H, Kiyotani K et al. (2005). "Eighteen novel polymorphisms of the CYP2A13 gene in Japanese". Drug Metab. Pharmacokinet. 18 (1): 86–90. doi:10.2133/dmpk.18.86. PMID 15618722.
  • Smith BD, Sanders JL, Porubsky PR et al. (2007). "Structure of the human lung cytochrome P450 2A13". J. Biol. Chem. 282 (23): 17306–13. doi:10.1074/jbc.M702361200. PMID 17428784.